AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
EMA Lifts Suspension on Valneva's Chikungunya Vaccine for Older Adults
ByAinvest
Saturday, Jul 12, 2025 3:27 pm ET1min read
Valneva's chikungunya vaccine, Ixchiq, has had its suspension lifted by the European Medicines Agency (EMA) for adults aged 65 years and older. The suspension was previously paused in May due to safety concerns.
Valneva SE (NASDAQ: VALN) has announced that the European Medicines Agency (EMA) has lifted the suspension on its chikungunya vaccine, Ixchiq, for adults aged 65 years and older. The suspension, which was implemented in May due to safety concerns, has been lifted following a thorough review by the EMA's safety committee [1].The EMA's decision comes after an evaluation of the vaccine's benefits and risks, particularly in older adults who face a higher risk of severe chikungunya infection. The committee concluded that the vaccine should be administered only when there is a significant risk of chikungunya infection, following a careful consideration of the benefits and risks [1].
Chikungunya virus (CHIKV) is a mosquito-borne viral disease that causes fever, severe joint and muscle pain, headache, nausea, fatigue, and rash. Joint pain can be debilitating and may persist for weeks to years [4]. The disease has been identified in over 110 countries and has caused significant economic impact, particularly in the Americas [5].
Valneva SE, a specialty vaccine company, has been developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases. The company has a strong track record of advancing vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [2].
The lifting of the suspension on Ixchiq is a significant development for Valneva and the broader public health community, as it allows for the vaccination of a vulnerable population that is at increased risk of severe chikungunya disease. However, it is crucial to note that the vaccine should be administered only when there is a significant risk of infection, as determined by healthcare professionals [1].
References:
[1] https://seekingalpha.com/news/4466852-valnevas-chikungunya-vaccine-suspension-gets-lifted-for-older-adults
[2] https://www.globenewswire.com/news-release/2025/07/11/3114143/0/en/Valneva-Announces-Lifting-of-European-Medicines-Agency-s-Temporary-Restriction-on-Use-of-Chikungunya-Vaccine-IXCHIQ-in-Elderly.html
[4] https://jvi.asm.org/content/jvi/88/20/11644.full.pdf
[5] https://cmr.asm.org/content/31/1/e00104-16
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet